Welcome to our dedicated page for CareDx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CareDx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CareDx's regulatory disclosures and financial reporting.
CareDx, Inc. insider Peter Maag filed a notice to sell 9,122 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $423,091.13 for these shares and references 51,734,223 shares outstanding of CareDx common stock as of this notice.
The notice also reports prior sales of CareDx common stock by Peter Maag during August 2026, including transactions of 75,653 shares on August 4, 46,963 shares on August 5, and 27,332 shares on August 7, each with stated aggregate proceeds. Several tranches of restricted stock granted by the issuer between June 2023 and July 2024 are identified as the securities to be sold.
PETER MAAG filed to sell common stock of CDNA. The notice lists a proposed sale of 7,000 shares through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $317,112.60, against 51,734,223 shares outstanding as of the filing. It also details multiple common stock sales over the prior three months, including blocks of 75,653, 46,963, and 27,332 shares, each with corresponding dollar amounts.
CareDx, Inc. received an amended Schedule 13G from Baron Capital Group, Inc., its affiliates BAMCO, Inc. and Baron Capital Management, Inc., and Ronald Baron regarding ownership of CareDx common stock (CUSIP 14167L103).
The filing reports that Baron Capital Group, Inc. and Ronald Baron each beneficially own 1,937,326 shares of CareDx common stock, representing 3.75% of the class, with shared voting and dispositive power over all such shares and no sole voting or dispositive power. Within this total, BAMCO, Inc. has shared voting and dispositive power over 1,662,887 shares (about 3.22% of the class), and Baron Capital Management, Inc. has shared voting and dispositive power over 274,439 shares (about 0.53% of the class). The filing confirms that this ownership is now 5 percent or less of the outstanding common stock and that advisory clients of BAMCO and BCM have the economic rights to dividends and sale proceeds in their accounts.
CDNA insider Peter Maag filed to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of $329,505.40 on NASDAQ. The shares relate to restricted stock granted as compensation on 04/11/2023, 01/29/2024, and 02/03/2024. The filing also lists several recent sales, including 7,000 shares for $333,851.00 on 08/11/2026 and 75,653 shares for $3,576,851.19 on 08/04/2026.
CareDx, Inc. insider Peter Maag filed a notice to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $328,237.70. The issuer reports 51,734,223 shares outstanding of common stock, listed on NASDAQ. The shares to be sold relate to restricted stock awards dated December 31, 2023 (797 shares) and January 29, 2024 (6,203 shares). The filing also lists recent sales of common stock by Maag between August 4 and August 11, 2026, including transactions of 75,653 shares for $3,576,851.19 and 46,963 shares for $2,178,945.34.
CareDx, Inc. (CDNA) received a notice of proposed sale of common stock by insider Peter Maag under a planned transaction. The filing lists up to 7,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of 333851.00 as of 08/11/2026. It also reports prior common stock sales by Maag over the past three months, including 75,653 shares on 08/04/2026 for 3576851.19 and additional sales on 08/05/2026, 08/07/2026, and 08/10/2026.
CDNA insider Peter Maag filed a Form 144 indicating an intention to sell common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ. The notice covers 6,902 common shares, tied to restricted stock awards dated June 1, 2022 and February 3, 2023, with an aggregate market value of $328,949.32 as of August 10, 2026.
The filing also lists sales of common shares during the prior three months: 27,332 shares on August 7, 2026 for $1,252,491.63, 46,963 shares on August 5, 2026 for $2,178,945.34, and 75,653 shares on August 4, 2026 for $3,576,851.19.
Arthur Torres has filed a notice for the proposed sale of up to 4,200 shares of CDNA common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares, with an aggregate market value of $200,475.24 as of 08/10/2026, were acquired as restricted stock from the issuer on 06/10/2026. Over the prior three months, Torres reported sales of 6,484 shares for $128,977.78 on 05/15/2026 and 4,086 shares for $85,697.72 on 05/14/2026.
Neil Gagnon and affiliated entities report significant ownership in CareDx, Inc. common stock. Neil Gagnon is reported as beneficially owning 2,293,464 shares of CareDx common stock, representing 4.4% of the class. Gagnon Securities LLC reports beneficial ownership of 1,629,867 shares (3.2%), and Gagnon Advisors, LLC reports 408,837 shares (0.8%).
Neil Gagnon has sole voting and dispositive power over 149,317 shares and shared voting power over 1,946,659 shares, with shared dispositive power over 2,144,147 shares. The filing states that Gagnon Securities LLC and Gagnon Advisors, LLC, along with Mr. Gagnon, may be deemed to share voting and dispositive power over shares held in customer accounts and a private investment fund, while expressly disclaiming beneficial ownership of those securities.
CareDx, Inc. insider Peter Maag filed to sell shares of Common Stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services program. The notice covers 27,332 shares tied to a stock option exercise dated August 7, 2026, with sales on NASDAQ. It also lists prior three‑month sales of 46,963 shares on August 5, 2026 and 75,653 shares on August 4, 2026.